BAX - Baxter International Inc.

NYSE - NYSE Delayed Price. Currency in USD
66.95
+0.16 (+-0.07%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close67.00
Open67.02
Bid0.00 x 800
Ask66.78 x 1300
Day's Range66.54 - 67.51
52 Week Range61.05 - 78.38
Volume2,796,041
Avg. Volume3,915,149
Market Cap35.627B
Beta (3Y Monthly)1.21
PE Ratio (TTM)30.67
EPS (TTM)2.18
Earnings DateJan 31, 2019
Forward Dividend & Yield0.76 (1.14%)
Ex-Dividend Date2018-11-30
1y Target Est74.00
Trade prices are not sourced from all markets
  • Zacks20 hours ago

    Here's Why You Should Hold Baxter International (BAX) Now

    Baxter's (BAX) recent string of developments boost the stock while segmental softness is a concern.

  • See what the IHS Markit Score report has to say about Baxter International Inc.
    Markit21 hours ago

    See what the IHS Markit Score report has to say about Baxter International Inc.

    Baxter International Inc NYSE:BAX

  • How Medtronic’s Cardiac and Vascular Group Performed
    Market Realist21 hours ago

    How Medtronic’s Cardiac and Vascular Group Performed

    Medtronic’s (MDT) Cardiac & Vascular Group generated revenues of $2.9 billion in the second quarter of fiscal 2019 compared to $2.8 billion in the second quarter of fiscal 2018, reflecting ~3% YoY growth.

  • Will GE’s Healthcare Unit Spin-Off Increase Shareholder Wealth?
    Market Realist3 days ago

    Will GE’s Healthcare Unit Spin-Off Increase Shareholder Wealth?

    Why Has General Electric Stock Struggled in 2018? The Healthcare segment is the fourth-largest contributor to General Electric’s total revenues. As part of the company’s major restructuring plan in June, General Electric intends to spin off the segment and turn it into a standalone entity.

  • Zacks4 days ago

    Baxter & EFCNI Collaborate to Improve Care for Preterm Born

    Baxter's (BAX) latest move is likely to increase the use of Baxter's Numeta G13E triple-chamber PN product.

  • Hedge Funds Are Still Crazy About Baxter International Inc. (BAX)
    Insider Monkey6 days ago

    Hedge Funds Are Still Crazy About Baxter International Inc. (BAX)

    Many investors, including Paul Tudor Jones or Stan Druckenmiller, have been saying for a while now that the current market is overvalued due to a low interest rate environment that leads to companies swapping their equity for debt and focusing mostly on short-term performance such as beating the quarterly earnings estimates. In the fourth quarter, […]

  • Dan Loeb Sells Baxter International Shares at Strong Gain
    GuruFocus.com7 days ago

    Dan Loeb Sells Baxter International Shares at Strong Gain

    Daniel Loeb (Trades, Portfolio), whose fund is posting negative returns this year, reported on Wednesday that he unloaded a portion of one of his highly profitable bets, health care company Baxter International (BAX). Warning! GuruFocus has detected 1 Warning Sign with GOOG. The sale resulted from the "portfolio concentration level" it had reached in the portfolio of his hedge fund, Third Point.

  • Business Wire7 days ago

    Baxter Supports New EFCNI Standards in Newborn Care in Raising Awareness of Risks from Malnutrition

    Baxter International Inc. (BAX), a global leader in clinical nutrition, is collaborating with the European Foundation for the Care of Newborn Infants (EFCNI) to raise awareness for the new EFCNI standards that address the disparities in newborn care in Europe. EFCNI released the new European Standards of Care for Newborn Health last week.

  • Business Wire8 days ago

    Baxter Appoints Patricia Morrison and Amy Wendell to Its Board

    Baxter International Inc. (BAX), a leading global medical products company, today announced it has appointed Patricia B. (Patty) Morrison, former Cardinal Health executive vice president and chief information officer, and Amy A. Wendell, former Covidien senior vice president of strategy and business development, to its board of directors.

  • Business Wire10 days ago

    Baxter to Present at the 37th Annual J.P. Morgan Healthcare Conference

    Baxter International Inc. , a leading global medical products company, will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco. José E. Almeida, Baxter’s chairman and chief executive officer, is scheduled to present on Monday, January 7, 2019 at 10 a.m.

  • Baxter International Inc (NYSE:BAX): Has Recent Earnings Growth Beaten Long-Term Trend?
    Simply Wall St.13 days ago

    Baxter International Inc (NYSE:BAX): Has Recent Earnings Growth Beaten Long-Term Trend?

    Today I will examine Baxter International Inc’s (NYSE:BAX) latest earnings update (30 September 2018) and compare these figures against its performance over the past couple of years, in addition to Read More...

  • Edwards Lifesciences Stock: Analysts Remain Bullish
    Market Realist15 days ago

    Edwards Lifesciences Stock: Analysts Remain Bullish

    In November, among the 22 analysts covering Edwards Lifesciences (EW), 13 recommended a “buy” or higher rating, seven recommended a “hold” rating, and two recommended a “sell” or lower rating. The mean rating for Edwards Lifesciences stock is 2.32 with a target price of $161.53, which implies an upside potential of 4.5% over Edwards Lifesciences’ closing price of $154.52 on November 27.

  • MS Global Franchise Fund's Top 5 Buys in 3rd Quarter
    GuruFocus.com15 days ago

    MS Global Franchise Fund's Top 5 Buys in 3rd Quarter

    Fund adds to two existing positions and introduces three new holdings

  • GE’s Healthcare Unit Spin-Off to Maximize Shareholders’ Wealth
    Market Realist24 days ago

    GE’s Healthcare Unit Spin-Off to Maximize Shareholders’ Wealth

    General Electric’s (GE) Healthcare segment, which offers medical imaging and information technologies, biopharmaceutical manufacturing technologies, and patient monitoring systems, is one of the company’s better-performing units and is the fourth-largest contributor to its total revenue.

  • Baxter International: Analysts Remain Bullish on the Stock
    Market Realist25 days ago

    Baxter International: Analysts Remain Bullish on the Stock

    In November, among the 17 analysts covering Baxter International (BAX), ten analysts recommended a “buy” or a higher rating, five recommended a “hold” rating, and three recommended a “sell” rating. The mean rating for Baxter International stock is 2.29 with a target price of $73.27, which implies an upside potential of 11.3% over Baxter International’s closing price of $65.83 on November 15.

  • Analyzing Baxter International’s Operational Performance
    Market Realist28 days ago

    Analyzing Baxter International’s Operational Performance

    Baxter International’s (BAX) cost of sales decreased from $1.58 billion in the third quarter of 2017 to $1.53 billion in the third quarter. The company’s gross profit increased from $1.13 billion in the third quarter of 2017 to $1.24 billion in the third quarter due to the favorable product mix and manufacturing efficiencies.

  • What Baxter International’s Bottom-Line Trend Indicates
    Market Realist28 days ago

    What Baxter International’s Bottom-Line Trend Indicates

    Baxter International’s (BAX) net interest expense decreased from $14.0 million in the third quarter of 2017 to $11.0 million in the third quarter. The company’s net other income increased from $4.0 million in the third quarter of 2017 to $32.0 million in the third quarter. While the company incurred an income tax expense of $42.0 million in the third quarter of 2017, it received an income tax benefit of $138.0 million in the third quarter.

  • Baxter International: Why Investors Are Interested
    Market Realist28 days ago

    Baxter International: Why Investors Are Interested

    Fluctuations in Baxter International’s (BAX) stock price have kept investors interested in the stock in 2018. In this series, we’ll discuss Baxter International’s financials, analysts’ views on the stock, valuation metrics, and geographic performance. The company’s business units include renal care, medication delivery, pharmaceuticals, clinical nutrition, advanced surgery, and acute therapies.

  • Baxter (BAX) Launches Peri-Strips & Tisseel Prima, Shares Up
    Zacks29 days ago

    Baxter (BAX) Launches Peri-Strips & Tisseel Prima, Shares Up

    Baxter's (BAX) diversified surgical portfolio lends it a competitive edge in the MedTech space.

  • Business Wirelast month

    Baxter Unveils New Products at the ASMBS – Obesity Week Meeting to Help Surgeons Overcome Challenges During Bariatric Surgery

    Baxter International Inc. (BAX), a global leader in advancing surgical innovation, revealed its Peri-Strips Dry with Veritas (PSDV) Circular Staple Line Reinforcement with Secure Grip technology, the latest evolution in a product portfolio that has more than 20 years of proven clinical use in surgical buttressing and soft tissue repair. PSDV Circular is being showcased alongside the company’s comprehensive Advanced Surgery portfolio at the 2018 American Society for Metabolic and Bariatric Society (ASMBS) – Obesity Week meeting this week.

  • Inside General Electric’s Healthcare Business Unit Spin-Off Plan
    Market Realistlast month

    Inside General Electric’s Healthcare Business Unit Spin-Off Plan

    As part of its major restructuring plan, General Electric (GE) intends to spin off its Healthcare segment and turn it into a standalone entity. The company has planned the spin-off in a manner that maximizes shareholder wealth.

  • MarketWatchlast month

    Baxter board approves $2 billion increase to share buyback authorization

    Baxter International Inc. said Tuesday its board has approved a $2 billion increase to its share buyback authorization, bringing the total available to $3.4 billion. The medical products company's shares were up 1.1% premarket, but have fallen about 5% in 2018, while the S&P 500 has gained 2%.

  • Business Wirelast month

    Baxter Declares Quarterly Dividend and Announces Expanded Share Repurchase Authorization

    Baxter International Inc. (BAX), a leading global medical products company, announced today a quarterly cash dividend and an expanded authorization for its share repurchase program. Baxter’s Board of Directors has also approved a $2.0 billion increase in authorization for the company’s existing share repurchase plan. Based on these actions, the share repurchase plan has approximately $3.4 billion of repurchase authority available as of the date hereof to make repurchases pursuant to new or existing Rule 10b5-1 plans or otherwise.

  • Business Wirelast month

    Baxter Highlights Data at ISPOR Europe 2018 on Clinical and Economic Benefits When Addressing Malnutrition, Intraoperative Bleeding

    Studies examine cancer-related malnutrition and nutrition management in pre-term babies, as well as the use of hemostats in specific pancreatic and spinal surgeries